Skip to main content
Sign In
 


 

 Description

 

Dr Ridgway came to Colorado in 1985 from the Massachusetts General Hospital in Boston Massachusetts where he was head of the Thyroid Unit to become Head of the Division of Endocrinology, Metabolism, and Diabetes (1985-2007). He is the past President of the American Thyroid Association (1996-97) and past President of the Endocrine Society (2003-2004). Based at the University of Colorado Health Sciences Center, his basic research centers on thyrotropin (TSH), the major regulator of the thyroid gland. His laboratory utilizes state-of-the-art molecular techniques to understand the developmental and regulatory factors controlling the alpha and beta subunits of thyrotropin. In human disease, Dr. Ridgway's laboratory has a long interest in the production of the glycoprotein pituitary hormones by pituitary tumors. Originally these tumors were called non-functioning because they were not associated with classical clinical syndromes. However, improved methods have shown glycoprotein hormone production in 15-30% of pituitary tumors. In addition, Dr. Ridgway has a major interest in the peripheral actions of thyroid hormones on a variety of the processes in human disorders of the thyroid gland. He is particularly interested in alterations in cardiac, brain, pulmonary, skeletal muscle, hepatic and adipocyte function in patients with thyroid dysfunction, and their correction by appropriate therapies

Selected Publications 

  • Kerr J, Wood W, Ridgway EC. Basic science and clinical research advances in the pituitary transcription factors: Pit-1 and Prop-1. Curr Opin Endocrinol Diabetes Obes. 2008 Aug;15(4):359-63. PUBMED
  • Ridgway EC, Tomer Y, McLachlan SM. Update in thyroidology. J Clin Endocrinol Metab. 2007 Oct;92(10):3755-61 PUBMED
  • Sarapura VD, Wood WM, Woodmansee WW, Haakinson DJ, Dowding JM, Gordon DF, Ridgway EC. Pituitary tumors arising from glycoprotein hormone alpha-subunit-deficient mice contain transcription factors and receptors present in thyrotropes. Pituitary. 2006;9(1):11-8. PUBMED 
  • Charles MA, Saunders TL, Wood WM, Owens K, Parlow AF, Camper SA, Ridgway EC, Gordon DF. Pituitary-specific Gata2 knockout: effects on gonadotrope and thyrotrope function. Mol Endocrinol. 2006 Jun;20(6):1366-77 PUBMED
  • Christoffolete MA, Ribeiro R, Singru P, Fekete C, da Silva WS, Gordon DF, Huang SA, Crescenzi A, Harney JW, Ridgway EC, Larsen PR, Lechan RM, Bianco AC. Atypical expression of type 2 iodothyronine deiodinase in thyrotrophs explains the thyroxine-mediated pituitary thyrotropin feedback mechanism. Endocrinology. 2006 Apr;147(4):1735-43. PUBMED 
  • Gordon DF, Tucker EA, Tundwal K, Hall H, Wood WM, Ridgway EC. MED220/thyroid receptor-associated protein 220 functions as a transcriptional coactivator with Pit-1 and GATA-2 on the thyrotropin-beta promoter in thyrotropes. Mol Endocrinol. 2006 May;20(5):1073-89. PUBMED 
  • Woodmansee WW, Kerr JM, Tucker EA, Mitchell JR, Haakinson DJ, Gordon DF, Ridgway EC, Wood WM. The proliferative status of thyrotropes is dependent on modulation of specific cell cycle regulators by thyroid hormone. Endocrinology. 2006 Jan;147(1):272-82. PUBMED

Education

Coming Soon!

Reasearch Interests

 

·        Thyroid Disorders

·        Pituitary Disorders

·        Thyroid Cancer